

Systemic oncological treatments in patients with advanced pancreatic cancer: A scoping review and evidence map.

Supportive Care in Cancer

Salazar J (1), Bracchiglione J (1,2), Acosta-Dighero R (3), Meza N (2), Meade A (1), Quintana MJ (1,6), Requeijo C (1), Rodríguez-Grijalva G (1), Santero M (1), Selva A (4, 6), Solà I (1,5,6), Bonfill X (1,5,6), Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group.

- (1) Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain
- (2) Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Viña del Mar, Chile
- (3) Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile
- (4) Corporació Sanitària Parc Taulí, Sabadell, Spain
- (5) CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
- (6) Universitat Autònoma Barcelona, Barcelona, Spain.

Corresponding author: Xavier Bonfill Cosp, C/ Sant Antoni Maria Claret, 167, Pavelló 18, planta 0. 08025. Barcelona, España. Teléfono: +34 93 553 78 14 Fax: +34 93 553 78 09. xbonfill@santpau.cat

SEARCH STRATEGY FOR PUBMED

#1	("Gastrointestinal Neoplasms"[Mesh:NoExp] OR "Esophageal Neoplasms"[Mesh] OR "Stomach Neoplasms"[Mesh] OR "Liver Neoplasms"[Mesh] OR "Biliary Tract Neoplasms"[Mesh] OR "Pancreatic Neoplasms"[Mesh])
#2	((esophag*[Title] OR oesophag*[Title] OR stomach*[Title] OR gastric*[Title] OR gastroesophag*[Title] OR liver*[Title] OR hepatic*[Title] OR hepatocel*[Title] OR biliary tract*[Title] OR bile duct*[Title] OR gallbladder*[Title] OR gall bladder*[Title] OR pancreas*[Title] OR pancreatic*[Title] OR gastrointestinal*[Title]) AND (cancer*[Title] OR carcinom*[Title] OR neoplasm*[Title] OR tumor*[Title] OR tumour*[Title] OR malignan*[Title] OR adenocar*[Title] OR oncolog*[Title]))
#3	(#1 OR #2)
#4	("Palliative Care"[Mesh] OR "Terminal Care"[Mesh] OR "Neoplasm Metastasis"[Mesh])
#5	(palliative*[Title/Abstract] OR end of life*[Title/Abstract] OR end of live*[Title/Abstract] OR terminal*[Title/Abstract] OR metasta*[Title/Abstract] OR BSC[Title/Abstract] OR supportive care*[Title/Abstract] OR advanced*[Title/Abstract] OR unresect*[Title/Abstract] OR irresect*[Title/Abstract] OR nonresect*[Title/Abstract] OR non resect*[Title/Abstract] OR inopera*[Title/Abstract] OR unopera*[Title/Abstract] OR nonopera*[Title/Abstract] OR non opera*[Title/Abstract] OR non-opera*[Title/Abstract] OR stage IV[Title/Abstract])
#6	(#4 OR #5)
#7	(#3 AND #6)
#8	("Antineoplastic Protocols"[Mesh] OR "Chemoradiotherapy"[Mesh] OR "Induction Chemotherapy"[Mesh] OR "Maintenance Chemotherapy"[Mesh] OR "Consolidation Chemotherapy"[Mesh])
#9	(antineoplastic*[Title/Abstract] OR antineoplastic*[Title/Abstract] OR chemotherap*[Title/Abstract] OR chemoradiotherap*[Title/Abstract] OR radiochemotherap*[Title/Abstract] OR carboplatin*[Title/Abstract] OR cisplatin*[Title/Abstract] OR fluorouracil*[Title/Abstract] OR 5-FU[Title/Abstract] OR capecitabine*[Title/Abstract] OR docetaxel*[Title/Abstract] OR epirubicin*[Title/Abstract] OR irinotecan*[Title/Abstract] OR oxaliplatin*[Title/Abstract] OR paclitaxel*[Title/Abstract] OR trifluridine*[Title/Abstract] OR tipiracil*[Title/Abstract])

#10	(#8 OR #9)
#11	("Molecular Targeted Therapy"[Mesh] OR "Antibodies, Monoclonal"[Mesh] OR "Cancer Vaccines"[Mesh])
#12	(Target*[Title/Abstract] OR antibod*[Title/Abstract] OR immunotherap*[Title/Abstract] OR vaccine[Title/Abstract] OR vaccines[Title/Abstract] OR vaccination[Title/Abstract] OR HER2[Title/Abstract] OR HER-2[Title/Abstract] OR egfr[Title/Abstract] OR VEGF*[Title/Abstract] OR HGF[Title/Abstract] OR MET[Title/Abstract] OR claudin*[Title/Abstract] OR MMP9[Title/Abstract][JP1] OR tyrosine kinase inhibit*[Title/Abstract] OR trastuzumab[Title/Abstract] OR bevacizumab[Title/Abstract] OR rilotumumab[Title/Abstract] OR onartuzumab[Title/Abstract] OR ramucirumab[Title/Abstract] OR cetuximab[Title/Abstract] OR panitumumab[Title/Abstract] OR nimotuzumab[Title/Abstract] OR claudiximab[Title/Abstract] OR apatinib[Title/Abstract] OR lapatinib[Title/Abstract] OR regorafenib[Title/Abstract] OR everolimus[Title/Abstract] OR nivolumab[Title/Abstract] OR pembrolizumab[Title/Abstract] OR avelumab[Title/Abstract] OR durvalumab[Title/Abstract] OR ipilimumab[Title/Abstract] OR checkpoint inhibit*[Title/Abstract])
#13	(#11 OR #12)
#14	(#10 OR #13)
#15	(#7 AND #14)
#16	(animals [mh] NOT humans [mh])
#17	#15 NOT #16